About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Orum Therapeutics

News headline image
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Submits Registration Statement for KOSDAQ Listing
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum’s TPD²® Technology to Develop Novel Degrader-Antibody Conjugates
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Announces Presentation at ASH 2022 Annual Meeting
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics to Participate at Investor Conferences in September
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Presents Preclinical Data at AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Announces Formation of Scientific Advisory Board
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Appoints David Main to Board of Directors
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics to Participate in February Investor Conferences
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Appoints Olaf Christensen, M.D., as Chief Medical Officer
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer
From Orum Therapeutics
Via Business Wire
News headline image
Orum Therapeutics Appoints Jae Won Kim Chief Financial Officer
From Orum Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.